LILRB2 and cancer: HLA-B57:01:01 has a similar profile as HLA-B27 by binding to LILRB1, LILRB2 and KIR3DL1 receptors, both LILRB1 and LILRB2 checkpoint receptors are of wide clinical interest in cancer immunotherapy [34,35].